Dietrich John Pauls - Jun 1, 2024 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
President and CEO, Director
Signature
/s/ Amy E. Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jun 1, 2024
Transactions value $
$0
Form type
4
Date filed
6/3/2024, 04:41 PM
Previous filing
Jun 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 68.6K Jun 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +300K $0.00 300K Jun 1, 2024 Common Shares 300K $2.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
F2 Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025.